ReMedys Foundation has decided to accompany, on the path towards the clinic, a gene therapy project for the treatment of ALS caused by a mutation in the SOD1 gene (http://www.alsa.org/research/about-als-research/sod1.html, & http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4338957)
This project shall be based on the R&D framework in ALS, that ReMedys established one year ago starting with a project from the Weizmann Institute of Science, to clinically reposition Enoxacin. Of note that, in February 2015, the European Medicines Agency granted ReMedys with an Orphan Medicinal Product Designation for the use of Enoxacin in ALS.
The Enoxacin project is planned to enter early clinical tests within 2017.
The SOD1 gene therapy project is planned to enter the clinic by the end of 2018.